NLRP3 inflammasome: From a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases

Redox Biology

Volumn 4, Issue , 2015, Pages 296-307

  Abderrazak, Amna ^a,b,c   Syrovets, Tatiana ^d   Couchie, Dominique ^a,b,c   El Hadri, Khadija ^a,b,c   Friguet, Bertrand ^a,b,c   Simmet, Thomas ^d   Rouis, Mustapha ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b Université Pierre et Marie Curie   (France)

^c INSERM   (France)

^d UNIVERSITY OF ULM   (Germany)

Author keywords

Cardiovascular diseases; IL 18 (PDB id: Q14116); IL 1 (PDB id: P01584, P10749); NLRP3 inflammasome (PDB id: Q96P20); Obesity

Indexed keywords

CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 1BETA; THIOREDOXIN INTERACTING PROTEIN; CARRIER PROTEIN; INTERLEUKIN 18; NLRP3 PROTEIN, HUMAN; TXNIP PROTEIN, HUMAN;

CARDIOVASCULAR DISEASE; CELLULAR STRESS SIGNAL; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG TARGETING; ENDOPLASMIC RETICULUM STRESS; GENE MUTATION; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; INFLAMMATORY DISEASE; MOLECULAR INTERACTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DOMAIN; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; REVIEW; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; METABOLISM; MUTATION; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOVASCULAR DISEASES; CARRIER PROTEINS; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION REGULATION; HUMANS; INFLAMMASOMES; INFLAMMATION; INTERLEUKIN-18; INTERLEUKIN-1BETA; MUTATION; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; OBESITY; OXIDATIVE STRESS; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION;

EID: 84925047701     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2015.01.008     Document Type: Review

References (176)

1. Janeway C.A. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunology Today 1992, 13(1):11-16. http://www.ncbi.nlm.nih.gov/pubmed/1739426, 10.1016/0167-5699(92)90198-G.
2. Matzinger P. The danger model: a renewed sense of self. Science 2002, 296(5566):301-305. http://www.ncbi.nlm.nih.gov/pubmed/11951032, 10.1126/science.1071059.
3. Martinon F., Tschopp J. NLRs join TLRs as innate sensors of pathogens. Trends in Immunology 2005, 26(8):447-454. http://www.ncbi.nlm.nih.gov/pubmed/15967716, 10.1016/j.it.2005.06.004.
4. Martinon F., Burns K., Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Molecular Cell 2002, 10(2):417-426. http://www.ncbi.nlm.nih.gov/pubmed/12191486, 10.1016/S1097-2765(02)00599-3.
5. Dinarello C.A. A clinical perspective of IL-1beta as the gatekeeper of inflammation. European Journal of Immunology 2011, 41(5):1203-1217. http://www.ncbi.nlm.nih.gov/pubmed/21523780, 10.1002/eji.201141550.
6. Leemans J.C., Cassel S.L., Sutterwala F.S. Sensing damage by the NLRP3 inflammasome. Immunological Reviews 2011, 243(1):152-162. http://www.ncbi.nlm.nih.gov/pubmed/21884174, 10.1111/j.1600-065X.2011.01043.x.
7. Masters S.L., Simon A., Aksentijevich I., et al. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annual Review of Immunology 2009, 27:621-668. http://www.ncbi.nlm.nih.gov/pubmed/19302049, 10.1146/annurev.immunol.25.022106.141627.
8. Dinarello C.A. IL-1: discoveries, controversies and future directions. European Journal of Immunology 2010, 40(3):599-606. http://www.ncbi.nlm.nih.gov/pubmed/20201008, 10.1002/eji.201040319.
9. Strowig T., Henao-Mejia J., Elinav E., et al. Inflammasomes in health and disease. Nature 2012, 481(7381):278-286. http://www.ncbi.nlm.nih.gov/pubmed/22258606, 10.1038/nature10759.
10. De Alba E. Structure and interdomain dynamics of apoptosis-associated speck-like protein containing a CARD (ASC). Journal of Biological Chemistry 2009, 284(47):32932-32941. http://www.ncbi.nlm.nih.gov/pubmed/19759015, 10.1074/jbc.M109.024273.
11. Gross O., Thomas C.J., Guarda G., et al. The inflammasome: an integrated view. Immunological Reviews 2011, 243(1):136-151. http://www.ncbi.nlm.nih.gov/pubmed/21884173, 10.1111/j.1600-065X.2011.01046.x.
12. Masumoto J., Dowds T.A., Schaner P., et al. ASC is an activating adaptor for NF-kappa B and caspase-8-dependent apoptosis. Biochemical and Biophysical Research Communications 2003, 303(1):69-73. http://www.ncbi.nlm.nih.gov/pubmed/12646168.
13. Ohtsuka T., Ryu H., Minamishima Y.A., et al. ASC is a Bax adaptor and regulates the p53-Bax mitochondrial apoptosis pathway. Nature Cell Biology 2004, 6(2):121-128. http://www.ncbi.nlm.nih.gov/pubmed/14730312, 10.1038/ncb1087.
14. Richards N., Schaner P., Diaz A., et al. Interaction between pyrin and the apoptotic speck protein (ASC) modulates ASC-induced apoptosis. Journal of Biological Chemistry 2001, 276(42):39320-39329. http://www.ncbi.nlm.nih.gov/pubmed/11498534, 10.1074/jbc.M104730200.
15. Masumoto J., Taniguchi S., Ayukawa K., et al. ASC, a novel 22-kDa protein, aggregates during apoptosis of human promyelocytic leukemia HL-60 cells. Journal of Biological Chemistry 1999, 274(48):33835-33838. http://www.ncbi.nlm.nih.gov/pubmed/10567338, 10.1074/jbc.274.48.33835.
16. Masumoto J., Taniguchi S., Nakayama J., et al. Expression of apoptosis-associated speck-like protein containing a caspase recruitment domain, a pyrin N-terminal homology domain-containing protein, in normal human tissues. Journal of Histochemistry and Cytochemistry 2001, 49(10):1269-1275. http://www.ncbi.nlm.nih.gov/pubmed/11561011, 10.1177/002215540104901009.
17. Srinivasula S.M., Poyet J.L., Razmara M., et al. The pyrin-CARD protein ASC is an activating adaptor for caspase-1. Journal of Biological Chemistry 2002, 277(24):21119-21122. http://www.ncbi.nlm.nih.gov/pubmed/11967258, 10.1074/jbc.C200179200.
18. Fernandes-Alnemri T., Wu J., Yu J.W., et al. The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death and Differentiation 2007, 14(9):1590-1604. http://www.ncbi.nlm.nih.gov/pubmed/17599095, 10.1038/sj.cdd.4402194.
19. Cohen G.M. Caspases: the executioners of apoptosis. Biochemical Journal 1997, 326(1):1-16. http://www.ncbi.nlm.nih.gov/pubmed/9337844.
20. Martinon F., Tschopp J. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 2004, 117(5):561-574. http://www.ncbi.nlm.nih.gov/pubmed/15163405, 10.1016/j.cell.2004.05.004.
21. Nadiri A., Wolinski M.K., Saleh M. The inflammatory caspases: key players in the host response to pathogenic invasion and sepsis. Journal of Immunology 2006, 177(7):4239-4245. http://www.ncbi.nlm.nih.gov/pubmed/16982854, 10.4049/jimmunol.177.7.4239.
22. Martinon F., Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death and Differentiation 2007, 14(1):10-22. http://www.ncbi.nlm.nih.gov/pubmed/16977329, 10.1038/sj.cdd.4402038.
23. Saleh M., Vaillancourt J.P., Graham R.K., et al. Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. Nature 2004, 429(6987):75-79. http://www.ncbi.nlm.nih.gov/pubmed/15129283, 10.1038/nature02451.
24. Park H.H., Wu H. Crystal structure of RAIDD death domain implicates potential mechanism of PIDDosome assembly. Journal of Molecular Biology 2006, 357(2):358-364. http://www.ncbi.nlm.nih.gov/pubmed/16434054, 10.1016/j.jmb.2005.12.082.
25. Park H.H., Lo Y.C., Lin S.C., et al. The death domain superfamily in intracellular signaling of apoptosis and inflammation. Annual Review of Immunology 2007, 25:561-586. http://www.ncbi.nlm.nih.gov/pubmed/17201679, 10.1146/annurev.immunol.25.022106.141656.
26. Vajjhala P.R., Mirams R.E., Hill J.M. Multiple binding sites on the pyrin domain of ASC protein allow self-association and interaction with NLRP3 protein. Journal of Biological Chemistry 2012, 287(50):41732-41743. http://www.ncbi.nlm.nih.gov/pubmed/23066025, 10.1074/jbc.M112.381228.
27. Liepinsh E., Barbals R., Dahl E., et al. The death-domain fold of the ASC pyrin domain, presenting a basis for pyrin/pyrin recognition. Journal of Molecular Biology 2003, 332(5):1155-1163. http://www.ncbi.nlm.nih.gov/pubmed/14499617, 10.1016/j.jmb.2003.07.007.
28. Bae J.Y., Park H.H. Crystal structure of NALP3 protein pyrin domain (PYD) and its implications in inflammasome assembly. Journal of Biological Chemistry 2011, 286(45):39528-39536. http://www.ncbi.nlm.nih.gov/pubmed/21880711, 10.1074/jbc.M111.278812.
29. Taxman D.J., Huang M.T., Ting J.P. Inflammasome inhibition as a pathogenic stealth mechanism. Cell Host Microbe 2010, 8(1):7-11. http://www.ncbi.nlm.nih.gov/pubmed/20638636, 10.1016/j.chom.2010.06.005.
30. Stehlik C., Dorfleutner A. COPs and POPs: modulators of inflammasome activity. Journal of Immunology 2007, 179(12):7993-7998. http://www.ncbi.nlm.nih.gov/pubmed/18056338, 10.4049/jimmunol.179.12.7993.
31. Stehlik C., Krajewska M., Welsh K., et al. The PAAD/PYRIN-only protein POP1/ASC2 is a modulator of ASC-mediated nuclear-factor-kappa B and pro-caspase-1 regulation. Biochemical Journal 2003, 373(1):101-113. http://www.ncbi.nlm.nih.gov/pubmed/12656673, 10.1042/BJ20030304.
32. Dorfleutner A., Bryan N.B., Talbott S.J., et al. Cellular pyrin domain-only protein 2 is a candidate regulator of inflammasome activation. Infection and Immunity 2007, 75(3):1484-1492. http://www.ncbi.nlm.nih.gov/pubmed/17178784, 10.1128/IAI.01315-06.
33. Johnston J.B., Barrett J.W., Nazarian S.H., et al. A poxvirus-encoded pyrin domain protein interacts with ASC-1 to inhibit host inflammatory and apoptotic responses to infection. Immunity 2005, 23(6):587-598. http://www.ncbi.nlm.nih.gov/pubmed/16356857, 10.1016/j.immuni.2005.10.003.
34. Schroder K., Tschopp J. The inflammasomes. Cell 2010, 140(6):821-832. http://www.ncbi.nlm.nih.gov/pubmed/20303873, 10.1016/j.cell.2010.01.040.
35. Kanneganti T.D., Body-Malapel M., Amer A., et al. Critical role for cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA. Journal of Biological Chemistry 2006, 281(48):36560-36568. http://www.ncbi.nlm.nih.gov/pubmed/17008311, 10.1074/jbc.M607594200.
36. Kanneganti T.D., Ozören N., Body-Malapel M., et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 2006, 440(7081):233-236. http://www.ncbi.nlm.nih.gov/pubmed/16407888, 10.1038/nature04517.
37. Sutterwala F.S., Ogura Y., Szczepanik M., et al. Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 2006, 24(3):317-327. http://www.ncbi.nlm.nih.gov/pubmed/16546100, 10.1016/j.immuni.2006.02.004.
38. Duncan J.A., Gao X., Huang M.T., et al. Neisseria gonorrhoeae activates the proteinase cathepsin B to mediate the signaling activities of the NLRP3 and ASC-containing inflammasome. Journal of Immunology 2009, 182(10):6460-6469. http://www.ncbi.nlm.nih.gov/pubmed/19414800, 10.4049/jimmunol.0802696.
39. Di Paolo N.C., Miao E.A., Iwakura Y., et al. Virus binding to a plasma membrane receptor triggers interleukin-1alpha-mediated proinflammatory macrophage response in vivo. Immunity 2009, 31(1):110-121. http://www.ncbi.nlm.nih.gov/pubmed/19576795, 10.1016/j.immuni.2009.04.015.
40. Muruve D.A., Pétrilli V., Zaiss A.K., et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 2008, 452(7183):103-107. http://www.ncbi.nlm.nih.gov/pubmed/18288107, 10.1038/nature06664.
41. Martinon F., Agostini L., Meylan E., et al. Identification of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. Current Biology 2004, 14(21):1929-1934.
42. Hoegen T., Tremel N., Klein M., et al. The NLRP3 inflammasome contributes to brain injury in pneumococcal meningitis and is activated through ATP-dependent lysosomal cathepsin B release. Journal of Immunology 2011, 187(10):5440-5451. http://www.ncbi.nlm.nih.gov/pubmed/22003197, 10.4049/jimmunol.1100790.
43. Mariathasan S., Weiss D.S., Newton K., et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006, 440(7081):228-232. http://www.ncbi.nlm.nih.gov/pubmed/16407890, 10.1038/nature04515.
44. Dostert C., Pétrilli V., Van Bruggen R., et al. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008, 320(5876):674-677. http://www.ncbi.nlm.nih.gov/pubmed/18403674, 10.1126/science.1156995.
45. Hornung V., Bauernfeind F., Halle A., et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nature Immunology 2008, 9(8):847-856. http://www.ncbi.nlm.nih.gov/pubmed/18604214, 10.1038/ni.1631.
46. Lunov O., Syrovets T., Loos C., et al. Amino-functionalized polystyrene nanoparticles activate the NLRP3 inflammasome in human macrophages. ACS Nano 2011, 5(12):9648-9657. http://www.ncbi.nlm.nih.gov/pubmed/22111911, 10.1021/nn203596e.
47. Kool M., Pétrilli V., De Smedt T., et al. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. Journal of Immunology 2008, 181(6):3755-3759. http://www.ncbi.nlm.nih.gov/pubmed/18768827, 10.4049/jimmunol.181.6.3755.
48. Feldmeyer L., Keller M., Niklaus G., et al. The inflammasome mediates UVB-induced activation and secretion of interleukin-1beta by keratinocytes. Current Biology 2007, 17(13):1140-1145. http://www.ncbi.nlm.nih.gov/pubmed/17600714, 10.1016/j.cub.2007.05.074.
49. Martinon F., Pétrilli V., Mayor A., et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440(7081):237-241. http://www.ncbi.nlm.nih.gov/pubmed/16407889, 10.1038/nature04516.
50. Yamasaki K., Muto J., Taylor K.R., et al. NLRP3/cryopyrin is necessary for interleukin-1beta (IL-1beta) release in response to hyaluronan, an endogenous trigger of inflammation in response to injury. Journal of Biological Chemistry 2009, 284(19):12762-12771. http://www.ncbi.nlm.nih.gov/pubmed/19258328, 10.1074/jbc.M806084200.
51. Halle A., Hornung V., Petzold G.C., et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nature Immunology 2008, 9(8):857-865. http://www.ncbi.nlm.nih.gov/pubmed/18604209, 10.1038/ni.1636.
52. Li H., Ambade A., Re F. Cutting edge: necrosis activates the NLRP3 inflammasome. Journal of Immunology 2009, 183(3):1528-1532. http://www.ncbi.nlm.nih.gov/pubmed/19596994, 10.4049/jimmunol.0901080.
53. 2+ is a danger signal activating the NLRP3 inflammasome through G protein-coupled calcium sensing receptors. Nature Communications 2012, 3:1329.
54. 2+ and cAMP. Nature 2012, 492(7427):123-127. http://www.ncbi.nlm.nih.gov/pubmed/23143333, 10.1038/nature11588.
55. Cassel S.L., Eisenbarth S.C., Iyer S.S., et al. The Nalp3 inflammasome is essential for the development of silicosis. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(26):9035-9040. http://www.ncbi.nlm.nih.gov/pubmed/18577586, 10.1073/pnas.0803933105.
56. Cruz C.M., Rinna A., Forman H.J., et al. ATP activates a reactive oxygen species-dependent oxidative stress response and secretion of proinflammatory cytokines in macrophages. Journal of Biological Chemistry 2007, 282(5):2871-2879. http://www.ncbi.nlm.nih.gov/pubmed/17132626, 10.1074/jbc.M608083200.
57. Pétrilli V., Papin S., Dostert C., et al. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death and Differentiation 2007, 14(9):1583-1589. http://www.ncbi.nlm.nih.gov/pubmed/17599094, 10.1038/sj.cdd.4402195.
58. Gross O., Poeck H., Bscheider M., et al. Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature 2009, 459(7245):433-436. http://www.ncbi.nlm.nih.gov/pubmed/19339971, 10.1038/nature07965.
59. Shio M.T., Eisenbarth S.C., Savaria M., et al. Malarial hemozoin activates the NLRP3 inflammasome through Lyn and Syk kinases. PLOS Pathogens 2009, 5(8):e1000559. 10.1371/journal.ppat.1000559.
60. Kowaltowski A.J., de Souza-Pinto N.C., Castilho R.F., et al. Mitochondria and reactive oxygen species. Free Radical Biology and Medicine 2009, 47(4):333-343. http://www.ncbi.nlm.nih.gov/pubmed/19427899, 10.1016/j.freeradbiomed.2009.05.004.
61. Shimada K., Crother T.R., Karlin J., et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 2012, 36(3):401-414. http://www.ncbi.nlm.nih.gov/pubmed/22342844, 10.1016/j.immuni.2012.01.009.
62. Rubartelli A. Redox control of NLRP3 inflammasome activation in health and disease. Journal of Leukocyte Biology 2012, 92(5):951-958.
63. Zhou R., Tardivel A., Thorens B., et al. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nature Immunology 2010, 11(2):136-140. http://www.ncbi.nlm.nih.gov/pubmed/20023662, 10.1038/ni.1831.
64. Masters S.L., Dunne A., Subramanian S.L., et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nature Immunology 2010, 11(10):897-904. http://www.ncbi.nlm.nih.gov/pubmed/20835230, 10.1038/ni.1935.
65. McGonagle D., Savic S., McDermott M.F. The NLR network and the immunological disease continuum of adaptive and innate immune-mediated inflammation against self. Seminars in Immunopathology 2007, 29(3):303-313. http://www.ncbi.nlm.nih.gov/pubmed/17805542, 10.1007/s00281-007-0084-1.
66. Yu J.R., Leslie K.S. Cryopyrin-associated periodic syndrome: an update on diagnosis and treatment response. Current Allergy and Asthma Reports 2011, 11(1):12-20.
67. Muckle T.J., Wellsm Urticaria, deafness, and amyloidosis: a new heredo-familial syndrome. Quarterly Journal of Medicine 1962, 31:235-248. http://www.ncbi.nlm.nih.gov/pubmed/14476827.
68. Huttenlocher A., Frieden I.J., Emery H. Neonatal onset multisystem inflammatory disease. Journal of Rheumatology 1995, 22(6):1171-1173. http://www.ncbi.nlm.nih.gov/pubmed/7674249.
69. Aksentijevich I., D Putnam C., Remmers E.F., et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis & Rheumatology 2007, 56(4):1273-1285. http://www.ncbi.nlm.nih.gov/pubmed/17393462, 10.1002/art.22491.
70. Shinkai K., McCalmont T.H., Leslie K.S. Cryopyrin-associated periodic syndromes and autoinflammation. Clinical and Experimental Dermatology 2008, 33(1):1-9. http://www.ncbi.nlm.nih.gov/pubmed/17927785, 10.1111/j.1365-2230.2007.02540.x.
71. Agostini L., Martinon F., Burns K., et al. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004, 20(3):319-325. http://www.ncbi.nlm.nih.gov/pubmed/15030775, 10.1016/S1074-7613(04)00046-9.
72. Masters S.L., Lobito A.A., Chae J., et al. Recent advances in the molecular pathogenesis of hereditary recurrent fevers. Current Opinion in Allergy and Clinical Immunology 2006, 6(6):428-433. http://www.ncbi.nlm.nih.gov/pubmed/17088647, 10.1097/ACI.0b013e3280109b57.
73. Goldbach-Mansky R., Dailey N.J., Canna S.W., et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. New England Journal of Medicine 2006, 355(6):581-592. http://www.ncbi.nlm.nih.gov/pubmed/16899778, 10.1056/NEJMoa055137.
74. Hawkins P.N., Lachmann H.J., McDermott M.F. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. New England Journal of Medicine 2003, 348(25):2583-2584. http://www.ncbi.nlm.nih.gov/pubmed/12815153, 10.1056/NEJM200306193482523.
75. Hoffman H.M., Rosengren S., Boyle D.L., et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004, 364(9447):1779-1785. http://www.ncbi.nlm.nih.gov/pubmed/15541451, 10.1016/S0140-6736(04)17401-1.
76. McDermott M.F., Tschopp J. From inflammasomes to fevers, crystals and hypertension: how basic research explains inflammatory diseases. Trends in Molecular Medicine 2007, 13(9):381-388. http://www.ncbi.nlm.nih.gov/pubmed/17822957, 10.1016/j.molmed.2007.07.005.
77. Liu J., Smith C.L., DeRyckere D., et al. Structure and function of Cdc6/Cdc18: implications for origin recognition and checkpoint control. Molecular Cell 2000, 6(3):637-648. http://www.ncbi.nlm.nih.gov/pubmed/11030343, 10.1016/S1097-2765(00)00062-9.
78. Albrecht M., Domingues F.S., Schreiber S., et al. Structural localization of disease-associated sequence variations in the NACHT and LRR domains of PYPAF1 and NOD2. FEBS Letters 2003, 554(3):520-528. http://www.ncbi.nlm.nih.gov/pubmed/14623123, 10.1016/S0014-5793(03)01222-5.
79. Duncan J.A., Bergstralh D.T., Wang Y., et al. Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(19):8041-8046. http://www.ncbi.nlm.nih.gov/pubmed/17483456, 10.1073/pnas.0611496104.
80. Faustin B., Lartigue L., Bruey J.M., et al. Reconstituted NALP1 inflammasome reveals two-step mechanism of caspase-1 activation. Molecular Cell 2007, 25(5):713-724. http://www.ncbi.nlm.nih.gov/pubmed/17349957, 10.1016/j.molcel.2007.01.032.
81. So A., De Smedt T., Revaz S., et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Research & Therapy 2007, 9(2):R28. http://www.ncbi.nlm.nih.gov/pubmed/17352828, 10.1186/ar2143.
82. Stahl N., Radin A., Mellis S. Rilonacept -CAPS and beyond. Annals of the New York Academy of Sciences 2009, 1182:124-134. http://www.ncbi.nlm.nih.gov/pubmed/20074281, 10.1111/j.1749-6632.2009.05074.x.
83. Lachmann H.J., Kone-Paut I., Kuemmerle-Deschner J.B., et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. New England Journal of Medicine 2009, 360(23):2416-2425. http://www.ncbi.nlm.nih.gov/pubmed/19494217, 10.1056/NEJMoa0810787.
84. Horng T., Hotamisligil G.S. Linking the inflammasome to obesity-related disease. Nature Medicine 2011, 17(2):164-165. http://www.ncbi.nlm.nih.gov/pubmed/21297609, 10.1038/nm0211-164.
85. Choi A.M., Nakahira K. Dampening insulin signaling by an NLRP3 'meta-flammasome'. Nature Immunology 2011, 12(5):379-380. http://www.ncbi.nlm.nih.gov/pubmed/21502990, 10.1038/ni.2028.
86. Vandanmagsar B., Youm Y.H., Ravussin A., et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nature Medicine 2011, 17(2):179-188. http://www.ncbi.nlm.nih.gov/pubmed/21217695, 10.1038/nm.2279.
87. Stienstra R., Joosten L.A., Koenen T., et al. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metabolism 2010, 12(6):593-605. http://www.ncbi.nlm.nih.gov/pubmed/21109192, 10.1016/j.cmet.2010.11.011.
88. Stienstra R., van Diepen J.A., Tack C.J., et al. Inflammasome is a central player in the induction of obesity and insulin resistance. Proceedings of the National Academy of Sciences of the United States of America 2011, 108(37):15324-15329. http://www.ncbi.nlm.nih.gov/pubmed/21876127, 10.1073/pnas.1100255108.
89. Youm Y.H., Adijiang A., Vandanmagsar B., et al. Elimination of the NLRP3-ASC inflammasome protects against chronic obesity-induced pancreatic damage. Endocrinology 2011, 152(11):4039-4045. http://www.ncbi.nlm.nih.gov/pubmed/21862613, 10.1210/en.2011-1326.
90. Henao-Mejia J., Elinav E., Strowig T., et al. Inflammasomes: far beyond inflammation. Nature Immunology 2012, 13(4):321-324. http://www.ncbi.nlm.nih.gov/pubmed/22430784, 10.1038/ni.2257.
91. Lumeng C.N., Bodzin J.L., Saltiel A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. Journal of Clinical Investigation 2007, 117(1):175-184. http://www.ncbi.nlm.nih.gov/pubmed/17200717, 10.1172/JCI29881.
92. Shah C., Yang G., Lee I., et al. Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1. Journal of Biological Chemistry 2008, 283(20):13538-13548. http://www.ncbi.nlm.nih.gov/pubmed/18359942, 10.1074/jbc.M709950200.
93. Boden G. Ceramide: a contributor to insulin resistance or an innocent bystander?. Diabetologia 2008, 51(7):1095-1096. http://www.ncbi.nlm.nih.gov/pubmed/18458870, 10.1007/s00125-008-1015-y.
94. Wen H., Gris D., Lei Y., et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nature Immunology 2011, 12(5):408-415. http://www.ncbi.nlm.nih.gov/pubmed/21478880, 10.1038/ni.2022.
95. Spranger J., Kroke A., Möhlig M., et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003, 52(3):812-817. http://www.ncbi.nlm.nih.gov/pubmed/12606524, 10.2337/diabetes.52.3.812.
96. Maedler K., Sergeev P., Ris F., et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. Journal of Clinical Investigation 2002, 110(6):851-860. http://www.ncbi.nlm.nih.gov/pubmed/12235117, 10.1172/JCI15318.
97. Maedler K., Spinas G.A., Lehmann R., et al. Glucose induces beta-cell apoptosis via upregulation of the Fas receptor in human islets. Diabetes 2001, 50(8):1683-1690. http://www.ncbi.nlm.nih.gov/pubmed/11473025, 10.2337/diabetes.50.8.1683.
98. Morgan D., Oliveira-Emilio H.R., Keane D., et al. Glucose, palmitate and pro-inflammatory cytokines modulate production and activity of a phagocyte-like NADPH oxidase in rat pancreatic islets and a clonal beta cell line. Diabetologia 2007, 50(2):359-369. http://www.ncbi.nlm.nih.gov/pubmed/17151863, 10.1007/s00125-006-0462-6.
99. Nishikawa T., Araki E. Impact of mitochondrial ROS production in the pathogenesis of diabetes mellitus and its complications. Antioxidants & Redox Signaling 2007, 9(3):343-353. http://www.ncbi.nlm.nih.gov/pubmed/17184177, 10.1089/ars.2007.9.ft-19.
100. Zhou F., Gomi M., Fujimoto M., et al. Attenuation of neuronal degeneration in thioredoxin-1 overexpressing mice after mild focal ischemia. Brain Research 2009, 1272:62-70. http://www.ncbi.nlm.nih.gov/pubmed/19328186, 10.1016/j.brainres.2009.03.023.
101. Wu N., Zheng B., Shaywitz A., et al. AMPK-dependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1. Molecular Cell 2013, 49(6):1167-1175. http://www.ncbi.nlm.nih.gov/pubmed/23453806, 10.1016/j.molcel.2013.01.035.
102. Abais J.M., Xia M., Zhang Y., et al. Redox Regulation of NLRP3 inflammasomes: ROS as trigger or effector?. Antioxidants & Redox Signaling 2014, http://www.ncbi.nlm.nih.gov/pubmed/25330206, 10.1089/ars.2014.5994.
103. Mihaylova M.M., Shaw R.J. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nature Cell Biology 2011, 13(9):1016-1023. http://www.ncbi.nlm.nih.gov/pubmed/21892142, 10.1038/ncb2329.
104. Viollet B., Athea Y., Mounier R., et al. AMPK: lessons from transgenic and knockout animals. Frontiers in Bioscience (Landmark Edition) 2009, 14:19-44.
105. Kawaguchi T., Osatomi K., Yamashita H., et al. Mechanism for fatty acid "sparing" effect on glucose-induced transcription: regulation of carbohydrate-responsive element-binding protein by AMP-activated protein kinase. Journal of Biological Chemistry 2002, 277(6):3829-3835. http://www.ncbi.nlm.nih.gov/pubmed/11724780, 10.1074/jbc.M107895200.
106. Schroder K., Zhou R., Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger?. Science 2010, 327(5963):296-300. http://www.ncbi.nlm.nih.gov/pubmed/20075245, 10.1126/science.1184003.
107. Koenen T.B., Stienstra R., van Tits L.J., et al. Hyperglycemia activates caspase-1 and TXNIP-mediated IL-1beta transcription in human adipose tissue. Diabetes 2011, 60(2):517-524. http://www.ncbi.nlm.nih.gov/pubmed/21270263, 10.2337/db10-0266.
108. Westermark P., Andersson A., Westermark G.T. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiological Reviews 2011, 91(3):795-826. http://www.ncbi.nlm.nih.gov/pubmed/21742788, 10.1152/physrev.00042.2009.
109. Zraika S., Hull R.L., Udayasankar J., et al. Oxidative stress is induced by islet amyloid formation and time-dependently mediates amyloid-induced beta cell apoptosis. Diabetologia 2009, 52(4):626-635. http://www.ncbi.nlm.nih.gov/pubmed/19148619, 10.1007/s00125-008-1255-x.
110. Wen H., Ting J.P., O'Neill L.A. A role for the NLRP3 inflammasome in metabolic diseases - Did Warburg miss inflammation?. Nature Immunology 2012, 13(4):352-357. http://www.ncbi.nlm.nih.gov/pubmed/22430788, 10.1038/ni.2228.
111. Lusis A.J. Atherosclerosis. Nature 2000, 407(6801):233-241. http://www.ncbi.nlm.nih.gov/pubmed/11001066, 10.1038/35025203.
112. Fuster V., Kelly B.B., Vedanthan R. Global cardiovascular health: urgent need for an intersectoral approach. Journal of the American College of Cardiology 2011, 58(12):1208-1210. http://www.ncbi.nlm.nih.gov/pubmed/21903051, 10.1016/j.jacc.2011.05.038.
113. Reddy K.S. Cardiovascular diseases in the developing countries: dimensions, determinants, dynamics and directions for public health action. Public Health Nutrition 2002, 5(1A):231-237. http://www.ncbi.nlm.nih.gov/pubmed/12027289, 10.1079/PHN2001298.
114. Földes G., Liu A., Badiger R., et al. Innate immunity in human embryonic stem cells: comparison with adult human endothelial cells. PLOS One 2010, 5(5):e10501. http://www.ncbi.nlm.nih.gov/pubmed/20463927, 10.1371/journal.pone.0010501.
115. Schultz K., Murthy V., Tatro J.B., et al. Endogenous interleukin-1alpha promotes a proliferative and proinflammatory phenotype in human vascular smooth muscle cells. American Journal of Physiology - Heart and Circulatory Physiology 2007, 292(6):H2927-H2934. http://www.ncbi.nlm.nih.gov/pubmed/17293495, 10.1152/ajpheart.00700.2006.
116. Garg N.J. Inflammasomes in cardiovascular diseases. American Journal of Cardiovascular Disease 2011, 1(3):244-254. http://www.ncbi.nlm.nih.gov/pubmed/22254202.
117. Hirao K., Yumoto H., Takahashi K., et al. Roles of TLR2, TLR4, NOD2, and NOD1 in pulp fibroblasts. Journal of Dental Research 2009, 88(8):762-767. http://www.ncbi.nlm.nih.gov/pubmed/19734466, 10.1177/0022034509341779.
118. Boyd J.H., Mathur S., Wang Y., et al. Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflammatory response. Cardiovascular Research 2006, 72(3):384-393. http://www.ncbi.nlm.nih.gov/pubmed/17054926, 10.1016/j.cardiores.2006.09.011.
119. Kearney P.M., Whelton M., Reynolds K., et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365(9455):217-223. http://www.ncbi.nlm.nih.gov/pubmed/15652604, 10.1016/S0140-6736(05)17741-1.
120. Russo C., Olivieri O., Girelli D., et al. Anti-oxidant status and lipid peroxidation in patients with essential hypertension. Journal of Hypertension 1998, 16(9):1267-1271. http://www.ncbi.nlm.nih.gov/pubmed/9746113, 10.1097/00004872-199816090-00007.
121. Berry C., Brosnan M.J., Fennell J., et al. Oxidative stress and vascular damage in hypertension. Current Opinion in Nephrology and Hypertension 2001, 10(2):247-255. http://www.ncbi.nlm.nih.gov/pubmed/11224701, 10.1097/00041552-200103000-00014.
122. Romero J.C., Reckelhoff J.F. State-of-the-art lecture. Role of angiotensin and oxidative stress in essential hypertension. Hypertension 1999, 34(4 Pt 2):943-949. http://www.ncbi.nlm.nih.gov/pubmed/10523389.
123. Wilcox C.S. Reactive oxygen species: roles in blood pressure and kidney function. Current Hypertension Reports 2002, 4(2):160-166. http://www.ncbi.nlm.nih.gov/pubmed/11884272, 10.1007/s11906-002-0041-2.
124. Intengan H.D., Schiffrin E.L. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 2001, 38(3 Pt 2):581-587. http://www.ncbi.nlm.nih.gov/pubmed/11566935, 10.1161/hy09t1.096249.
125. Rodríguez-Iturbe B., Vaziri N.D., Herrera-Acosta J., et al. Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all. American Journal of Physiology - Renal Physiology 2004, 286(4):F606-F616. http://www.ncbi.nlm.nih.gov/pubmed/15001451, 10.1152/ajprenal.00269.2003.
126. Moreno M.U., San José G., Orbe J., et al. Preliminary characterisation of the promoter of the human p22(phox) gene: identification of a new polymorphism associated with hypertension. FEBS Letters 2003, 542(1-3):27-31. http://www.ncbi.nlm.nih.gov/pubmed/12729892.
127. Sela S., Mazor R., Amsalam M., et al. Primed polymorphonuclear leukocytes, oxidative stress, and inflammation antecede hypertension in the Sabra rat. Hypertension 2004, 44(5):764-769. http://www.ncbi.nlm.nih.gov/pubmed/15452031, 10.1161/01.HYP.0000144480.10207.34.
128. Scrivo R., Vasile M., Bartosiewicz I., et al. Inflammation as "common soil" of the multifactorial diseases. Autoimmunity Reviews 2011, 10(7):369-374. http://www.ncbi.nlm.nih.gov/pubmed/21195808, 10.1016/j.autrev.2010.12.006.
129. Omi T., Kumada M., Kamesaki T., et al. An intronic variable number of tandem repeat polymorphisms of the cold-induced autoinflammatory syndrome 1 (CIAS1) gene modifies gene expression and is associated with essential hypertension. European Journal of Human Genetics 2006, 14(12):1295-1305. http://www.ncbi.nlm.nih.gov/pubmed/16868559, 10.1038/sj.ejhg.5201698.
130. Levy J.H., Szlam F., Tanaka K.A., et al. Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding. Anesthesia & Analgesia 2012, 114(2):261-274. http://www.ncbi.nlm.nih.gov/pubmed/21965371, 10.1213/ANE.0b013e31822e1853.
131. Wassel C.L., Lange L.A., Keating B.J., et al. Association of genomic loci from a cardiovascular gene SNP array with fibrinogen levels in European Americans and African-Americans from six cohort studies: the Candidate Gene Association Resource (CARe). Blood 2011, 117(1):268-275. http://www.ncbi.nlm.nih.gov/pubmed/20978265, 10.1182/blood-2010-06-289546.
132. Pomerantz B.J., Reznikov L.L., Harken A.H., et al. Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(5):2871-2876. http://www.ncbi.nlm.nih.gov/pubmed/11226333, 10.1073/pnas.041611398.
133. Kawaguchi M., Takahashi M., Hata T., et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation 2011, 123(6):594-604. http://www.ncbi.nlm.nih.gov/pubmed/21282498, 10.1161/CIRCULATIONAHA.110.982777.
134. Shigeoka A.A., Mueller J.L., Kambo A., et al. An inflammasome-independent role for epithelial-expressed Nlrp3 in renal ischemia-reperfusion injury. Journal of Immunology 2010, 185(10):6277-6285. http://www.ncbi.nlm.nih.gov/pubmed/20962258, 10.4049/jimmunol.1002330.
135. Zhu P., Duan L., Chen J., et al. Gene silencing of NALP3 protects against liver ischemia-reperfusion injury in mice. Human Gene Therapy 2011, 22(7):853-864. http://www.ncbi.nlm.nih.gov/pubmed/21128730, 10.1089/hum.2010.145.
136. Libby P. Inflammation in atherosclerosis. Nature 2002, 420(6917):868-874. http://www.ncbi.nlm.nih.gov/pubmed/12490960, 10.1038/nature01323.
137. Madamanchi N.R., Vendrov A., Runge M.S. Oxidative stress and vascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology 2005, 25(1):29-38. 10.1161/01.ATV.0000150649.39934.13.
138. Hansson G.K., Libby P. The immune response in atherosclerosis: a double-edged sword. Nature Reviews Immunology 2006, 6(7):508-519. http://www.ncbi.nlm.nih.gov/pubmed/16778830, 10.1038/nri1882.
139. Libby P. Atherosclerosis: the new view. Scientific American 2002, 286(5):46-55. http://www.ncbi.nlm.nih.gov/pubmed/11951331, 10.1038/scientificamerican0502-46.
140. Virchow R. Cellular pathology. As based upon physiological and pathological histology. lecture XVI -atheromatous affection of arteries. Nutrition Reviews 1858, 1989(47 (1)):23-25.
141. Ross R. Atherosclerosis is an inflammatory disease. American Heart Journal 1999, 138(5 Pt 2):S419-S420. http://www.ncbi.nlm.nih.gov/pubmed/10539839, 10.1016/S0002-8703(99)70266-8.
142. Small D.M. George Lyman Duff memorial lecture. Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry. Arteriosclerosis 1988, 8(2):103-129. http://www.ncbi.nlm.nih.gov/pubmed/3348756, 10.1161/01.ATV.8.2.103.
143. Libby P., Okamoto Y., Rocha V.Z., et al. Inflammation in atherosclerosis: transition from theory to practice. Circulation Journal 2010, 74(2):213-220. http://www.ncbi.nlm.nih.gov/pubmed/20065609, 10.1253/circj.CJ-09-0706.
144. Van Leuven S.I., Franssen R., Kastelein J.J., et al. Systemic inflammation as a risk factor for atherothrombosis. Rheumatology (Oxford) 2008, 47(1):3-7. http://www.ncbi.nlm.nih.gov/pubmed/17702769, 10.1093/rheumatology/kem202.
145. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. Journal of Biological Chemistry 1997, 272(34):20963-20966. http://www.ncbi.nlm.nih.gov/pubmed/9261091, 10.1074/jbc.272.34.20963.
146. Berliner J.A., Watson A.D. A role for oxidized phospholipids in atherosclerosis. New England Journal of Medicine 2005, 353(1):9-11. http://www.ncbi.nlm.nih.gov/pubmed/16000351, 10.1056/NEJMp058118.
147. Bochkov V.N., Oskolkova O.V., Birukov K.G., et al. Generation and biological activities of oxidized phospholipids. Antioxidants & Redox Signaling 2010, 12(8):1009-1059. http://www.ncbi.nlm.nih.gov/pubmed/19686040, 10.1089/ars.2009.2597.
148. Vora D.K., Fang Z.T., Liva S.M., et al. Induction of p-selectin by oxidized lipoproteins. separate effects on synthesis and surface expression. Circulation Research 1997, 80(6):810-818. http://www.ncbi.nlm.nih.gov/pubmed/9168783, 10.1161/01.RES.80.6.810.
149. Binder C.J., Chang M.K., Shaw P.X., et al. Innate and acquired immunity in atherogenesis. Nature Medicine 2002, 8(11):1218-1226. http://www.ncbi.nlm.nih.gov/pubmed/12411948, 10.1038/nm1102-1218.
150. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. New England Journal of Medicine 2005, 352(16):1685-1695. http://www.ncbi.nlm.nih.gov/pubmed/15843671, 10.1056/NEJMra043430.
151. Bogren H., Larsson K. An x-ray-diffraction study of crystalline cholesterol in some pathological deposits in man. Biochimica et Biophysica Acta 1963, 75:65-69.
152. Klinkner A.M., Waites C.R., Kerns W.D., et al. Evidence of foam cell and cholesterol crystal formation in macrophages incubated with oxidized LDL by fluorescence and electron microscopy. Journal of Histochemistry and Cytochemistry 1995, 43(10):1071-1078. http://www.ncbi.nlm.nih.gov/pubmed/7560885, 10.1177/43.10.7560885.
153. Tangirala R.K., Jerome W.G., Jones N.L., et al. Formation of cholesterol monohydrate crystals in macrophage-derived foam cells. Journal of Lipid Research 1994, 35(1):93-104. http://www.ncbi.nlm.nih.gov/pubmed/8138726.
154. Rajamäki K., Lappalainen J., Oörni K., et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLOS One 2010, 5(7):e11765. http://www.ncbi.nlm.nih.gov/pubmed/20668705, 10.1371/journal.pone.0011765.
155. Blankenberg S., Tiret L., Bickel C., et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002, 106(1):24-30. http://www.ncbi.nlm.nih.gov/pubmed/12093765, 10.1161/01.CIR.0000020546.30940.92.
156. Mallat Z., Corbaz A., Scoazec A., et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001, 104(14):1598-1603. http://www.ncbi.nlm.nih.gov/pubmed/11581135, 10.1161/hc3901.096721.
157. Galea J., Armstrong J., Gadsdon P., et al. Interleukin-1beta in coronary arteries of patients with ischemic heart disease. Arteriosclerosis, Thrombosis, and Vascular Biology 1996, 16(8):1000-1006. http://www.ncbi.nlm.nih.gov/pubmed/8696938, 10.1161/01.ATV.16.8.1000.
158. Moyer C.F., Sajuthi D., Tulli H., et al. Synthesis of IL-1 alpha and IL-1beta by arterial cells in atherosclerosis. American Journal of Pathology 1991, 138(4):951-960. http://www.ncbi.nlm.nih.gov/pubmed/2012178.
159. Duewell P., Kono H., Rayner K.J., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464(7293):1357-1361. http://www.ncbi.nlm.nih.gov/pubmed/20428172, 10.1038/nature08938.
160. Suzuki H., Kurihara Y., Takeya M., et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 1997, 386(6622):292-296. http://www.ncbi.nlm.nih.gov/pubmed/9069289, 10.1038/386292a0.
161. Febbraio M., Podrez E.A., Smith J.D., et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. Journal of Clinical Investigation 2000, 105(8):1049-1056. http://www.ncbi.nlm.nih.gov/pubmed/10772649, 10.1172/JCI9259.
162. Björkbacka H., Kunjathoor V.V., Moore K.J., et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nature Medicine 2004, 10(4):416-421. http://www.ncbi.nlm.nih.gov/pubmed/15034566, 10.1038/nm1008.
163. Michelsen K.S., Wong M.H., Shah P.K., et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(29):10679-10684. http://www.ncbi.nlm.nih.gov/pubmed/15249654, 10.1073/pnas.0403249101.
164. Tschopp J., Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production?. Nature Reviews Immunology 2010, 10(3):210-215. http://www.ncbi.nlm.nih.gov/pubmed/20168318, 10.1038/nri2725.
165. Latz E. The inflammasomes: mechanisms of activation and function. Current Opinion in Immunology 2010, 22(1):28-33. http://www.ncbi.nlm.nih.gov/pubmed/20060699, 10.1016/j.coi.2009.12.004.
166. Song J., Li J., Hou F., et al. Mangiferin inhibits endoplasmic reticulum stress-associated thioredoxin-interacting protein/NLRP3 inflammasome activation with regulation of AMPK in endothelial cells. Metabolism 2014, http://www.ncbi.nlm.nih.gov/pubmed/25499441, 10.1016/j.metabol.2014.11.008.
167. Mohamed I.N., Hafez S.S., Fairaq A., et al. Thioredoxin-interacting protein is required for endothelial NLRP3 inflammasome activation and cell death in a rat model of high-fat diet. Diabetologia 2014, 57(2):413-423. http://www.ncbi.nlm.nih.gov/pubmed/24201577, 10.1007/s00125-013-3101-z.
168. Wu J., Xu X., Li Y., et al. Quercetin, luteolin and epigallocatechin gallate alleviate TXNIP and NLRP3-mediated inflammation and apoptosis with regulation of AMPK in endothelial cells. European Journal of Pharmacology 2014, 745:59-68. http://www.ncbi.nlm.nih.gov/pubmed/25446924, 10.1016/j.ejphar.2014.09.046.
169. Menu P., Pellegrin M., Aubert J.F., et al. Atherosclerosis in ApoE-deficient mice progresses independently of the NLRP3 inflammasome. Cell Death & Disease 2011, 2:e137.
170. Kirii H., Niwa T., Yamada Y., et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2003, 23(4):656-660. http://www.ncbi.nlm.nih.gov/pubmed/12615675, 10.1161/01.ATV.0000064374.15232.C3.
171. Elhage R., Jawien J., Rudling M., et al. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovascular Research 2003, 59(1):234-240. http://www.ncbi.nlm.nih.gov/pubmed/12829194, 10.1016/S0008-6363(03)00343-2.
172. Whitman S.C., Ravisankar P., Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma. Circulation Research 2002, 90(2):E34-E38. http://www.ncbi.nlm.nih.gov/pubmed/11834721.
173. Kamari Y., Werman-Venkert R., Shaish A., et al. Differential role and tissue specificity of interleukin-1alpha gene expression in atherogenesis and lipid metabolism. Atherosclerosis 2007, 195(1):31-38. http://www.ncbi.nlm.nih.gov/pubmed/17173923, 10.1016/j.atherosclerosis.2006.11.026.
174. Carruth L.M., Demczuk S., Mizel S.B. Involvement of a calpain-like protease in the processing of the murine interleukin 1alpha precursor. Journal of Biological Chemistry 1991, 266(19):12162-12167. http://www.ncbi.nlm.nih.gov/pubmed/2061304.
175. De Nardo D., Latz E. NLRP3 inflammasomes link inflammation and metabolic disease. Trends in Immunology 2011, 32(8):373-379. http://www.ncbi.nlm.nih.gov/pubmed/21733753, 10.1016/j.it.2011.05.004.
176. Freigang S., Ampenberger F., Spohn G., et al. Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis. European Journal of Immunology 2011, 41(7):2040-2051. http://www.ncbi.nlm.nih.gov/pubmed/21484785, 10.1002/eji.201041316.